SGLT2 inhibitor treatment for non-obstructive hypertrophic cardiomyopathy
SGLT-inhibitors in patients with hypertrophic cardiomyopathy
['FUNDING_OTHER'] · UNIVERSITY OF PENNSYLVANIA · NIH-11161492
This project will try giving an SGLT2 diabetes medicine to people with non-obstructive hypertrophic cardiomyopathy to see if it is safe and helps symptoms and heart energy.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PENNSYLVANIA (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-11161492 on ClinicalTrials.gov |
What this research studies
If I join, I would take an SGLT2 inhibitor (a diabetes medication that may protect the heart) even if I don't have diabetes and attend regular clinic visits. Doctors will use heart imaging, blood tests including markers of heart energy, and symptom questionnaires to track safety, feasibility, and early signs of benefit. The team will closely monitor kidney function and other side effects and compare measures from before and after treatment. Early results would guide whether larger trials are warranted.
Who could benefit from this research
Good fit: Adults with symptomatic non-obstructive hypertrophic cardiomyopathy who can attend study visits, with or without diabetes, are the intended participants.
Not a fit: People with obstructive HCM, severe kidney disease, or other contraindications to SGLT2 inhibitors may not be eligible or benefit from this treatment.
Why it matters
Potential benefit: If successful, this approach could lessen symptoms and improve heart energy and outcomes for people with non-obstructive HCM.
How similar studies have performed: SGLT2 inhibitors have shown clear benefits in broad heart failure trials regardless of diabetes, but using them specifically for non-obstructive HCM is a novel application with limited prior data.
Where this research is happening
PHILADELPHIA, UNITED STATES
- UNIVERSITY OF PENNSYLVANIA — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DAY, SHARLENE M — UNIVERSITY OF PENNSYLVANIA
- Study coordinator: DAY, SHARLENE M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Adult-Onset Diabetes Mellitus